HOME > COMMENTARY
COMMENTARY
-
Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
-
Can Mid-sized Makers Break Away from Long-Listed Product Model?
August 19, 2016
-
MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
-
7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
May 27, 2016
-
Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application
March 31, 2016
-
Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
March 11, 2016
-
Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development
February 23, 2016
-
It’s Time to Squarely Discuss Proposed Penalty through Drug Price Cuts
February 3, 2016
-
Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews
January 18, 2016
-
Is 7.8% Drug Cost Cut Justifiable? Make “Huge Seller” Re-Pricing a Starter to Discuss This
January 12, 2016
-
High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed
November 27, 2015
-
Sakigake Designation System to Link Regulatory and Drug Pricing Systems; Could Result in Tougher Scrutiny for Designated Products
November 6, 2015
-
Data from Humanitarian Trials to Be Used in Product Reviews; Effective Use of Safety-Related Information Will Be Key
October 13, 2015
-
Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System
September 24, 2015
-
How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?
August 18, 2015
-
Leaner Sales Forces? Lower Profits? Drug Makers Face Tough Decision in 80% Generic Era
August 14, 2015
-
PMDA Poised to Tap Big Data to Refine Reviews, Safety Steps; Dedicated Center Eyed in 2018
August 12, 2015
-
Wholesalers Face Pressing Need to Retool Biz Strategy as Generics Gain Ground
July 21, 2015
-
Viable Third-Party Review System Required for Drug Makers’ Advertisements
July 7, 2015
-
Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
June 22, 2015
ページ
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
